Literature DB >> 34170460

Validation of the updated renal graded prognostic assessment (GPA) for patients with renal cancer brain metastases treated with gamma knife radiosurgery.

Laurens V Beerepoot1, Patrick E J Hanssens2, Niels J van Ruitenbeek3, Vincent K Y Ho4, Hans M Westgeest5.   

Abstract

INTRODUCTION: Prognosis of patients with brain metastasis (BM) from renal cell carcinoma (RCC) is relevant for treatment decisions and can be estimated with the Renal Graded Prognostic Assessment (GPA). The aim of this study is to validate the updated version of this instrument in a cohort treated with Gamma Knife radiosurgery (GKRS) without prior local intracerebral therapy.
METHODS: Between 2007 and 2018, 106 RCC patients with BM were treated with GKRS. They were categorized according to the updated Renal GPA. Overall survival (OS), distant intracranial failure and local failure were estimated using the Kaplan-Meier method and risk factors were identified with Cox proportional hazard regressions.
RESULTS: Median OS was 8.6 months. Median OS for GPA categories 0.0-1.0 (15%), 1.5-2.0 (12%), 2.5-3.0 (35%) and 3.5-4.0 (29%) was 2.9, 5.5, 8.1 and 20.4 months, respectively. Karnofsky performance status < 90, serum hemoglobin ≤ 12.5 g/dL, age > 65 years and time from primary diagnosis to brain metastasis < 1 year were significantly related with shorter survival, while presence of extracranial disease, the volume and total number of BM had no significant impact on OS. A total count of > 4 BM was the only predictive factor for distant intracranial failure, while none of the investigated factors predicted local failure.
CONCLUSIONS: This study confirms the updated Renal GPA in an independent cohort as a valuable instrument to estimate survival in patients with BM from RCC treated with GKRS.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Brain metastasis; Gamma knife radiosurgery; Prognosis; Renal cell carcinoma

Mesh:

Year:  2021        PMID: 34170460     DOI: 10.1007/s11060-021-03793-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  42 in total

1.  The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort.

Authors:  Maxine Sun; Guillermo De Velasco; Priscilla K Brastianos; Ayal A Aizer; Allison Martin; Raphael Moreira; Paul L Nguyen; Quoc-Dien Trinh; Toni K Choueiri
Journal:  Eur Urol Focus       Date:  2018-01-05

2.  Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases.

Authors:  I Alex Bowman; Alisha Bent; Tri Le; Alana Christie; Zabi Wardak; Yull Arriaga; Kevin Courtney; Hans Hammers; Samuel Barnett; Bruce Mickey; Toral Patel; Tony Whitworth; Strahinja Stojadinovic; Raquibul Hannan; Lucien Nedzi; Robert Timmerman; James Brugarolas
Journal:  Clin Genitourin Cancer       Date:  2018-12-05       Impact factor: 2.872

3.  Brain metastasis from renal cell carcinoma.

Authors:  O Bennani; S Derrey; O Langlois; H Castel; A Laquerriere; P Freger; F Proust
Journal:  Neurochirurgie       Date:  2014-03-14       Impact factor: 1.553

4.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

5.  [Should lumbar sympathectomy be associated with arterial reconstruction?].

Authors:  J van der Stricht; M Goldstein; J P Flamand; J Belenger
Journal:  Acta Chir Belg       Date:  1966-10       Impact factor: 1.090

6.  Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.

Authors:  M Bianchi; M Sun; C Jeldres; S F Shariat; Q-D Trinh; A Briganti; Z Tian; J Schmitges; M Graefen; P Perrotte; M Menon; F Montorsi; P I Karakiewicz
Journal:  Ann Oncol       Date:  2011-09-02       Impact factor: 32.976

7.  Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.

Authors:  Michael M Vickers; Hulayel Al-Harbi; Toni K Choueiri; Christian Kollmannsberger; Scott North; Mary MacKenzie; Jennifer J Knox; Brian I Rini; Daniel Y C Heng
Journal:  Clin Genitourin Cancer       Date:  2013-05-15       Impact factor: 2.872

8.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

9.  Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma.

Authors:  Jian Gao; Sen Zhao; Trond S Halstensen
Journal:  Oncol Rep       Date:  2016-04-20       Impact factor: 3.906

10.  Role of radiation therapy in the management of renal cell cancer.

Authors:  Angel I Blanco; Bin S Teh; Robert J Amato
Journal:  Cancers (Basel)       Date:  2011-10-26       Impact factor: 6.639

View more
  1 in total

1.  Stereotactic radiosurgery results for brain metastasis patients with renal cancer: A validity study of Renal Graded Prognostic Assessment and proposal of a new grading index (JLGK2101 Study).

Authors:  Rena Okuno-Ito; Masaaki Yamamoto; Yasunori Sato; Toru Serizawa; Jun Kawagishi; Takashi Shuto; Shoji Yomo; Atsuya Akabane; Kyoko Aoyagi; Takuya Kawabe; Yasuhiro Kikuchi; Kiyoshi Nakasaki; Masazumi Gondo; Yoshinori Higuchi; Toru Takebayashi
Journal:  Clin Transl Radiat Oncol       Date:  2021-11-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.